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Abstract
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in cholesterol
metabolism with high levels contributing to hypercholesterolemia. Cholesterol and sphingolipids are low in patients
with liver cirrhosis. Purpose of this study was to find associations of plasma PCSK9 with circulating cholesterol and
sphingolipid species and measures of liver disease severity in patients with liver cirrhosis.
Methods: PCSK9 protein levels were determined by ELISA in systemic vein (SVP), hepatic vein (HVP) and portal vein
plasma of patients with mostly alcoholic liver cirrhosis. PCSK9 and LDL-receptor protein expression were analysed in
cirrhotic and non-cirrhotic liver tissues.
Results: Serum PCSK9 was reduced in patients with liver cirrhosis in comparison to non-cirrhotic patients. In liver
cirrhosis, plasma PCSK9 was not correlated with Child-Pugh score, Model for End-Stage Liver Disease score, bilirubin
or aminotransferases. A negative association of SVP PCSK9 with albumin existed. PCSK9 protein in the liver did not
change with fibrosis stage and was even positively correlated with LDL-receptor protein levels. Ascites volume and
variceal size were not related to PCSK9 levels. Along the same line, transjugular intrahepatic shunt to lower portal
pressure did not affect PCSK9 concentrations in the three blood compartments. Serum cholesterol, sphingomyelin
and ceramide levels did not correlate with PCSK9. Stratifying patients by high versus low PCSK9 levels using the
median as cut-off, several cholesteryl ester species were even low in the subgroup with high PCSK9 levels. A few
sphingomyelin species were also reduced in the patients with PCSK9 levels above the median. PCSK9 is highly
expressed in the liver but systemic, portal and hepatic vein levels were similar. PCSK9 was not correlated with the
inflammatory proteins C-reactive protein, IL-6, galectin-3, resistin or pentraxin 3. Of note, HVP PCSK9 was positively
associated with HVP chemerin and negatively with HVP adiponectin levels.
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Conclusions: In the cohort of patients with liver cirrhosis mostly secondary to alcohol consumption high PCSK9
was associated with low levels of certain cholesteryl ester and sphingomyelin species. Positive correlations of PCSK9
and LDL-receptor protein in the liver of patients with chronic liver injury are consistent with these findings.
Keywords: Ceramide, Sphingomyelin, Chemerin, Model for end-stage liver disease score, Ascites, Varices, Alcoholic,
Hepatitis C
Introduction
Liver cirrhosis is the stage of chronic liver diseases with
irreversible organ damage. Chronic infections with hepa-
titis B or C virus, alcohol abuse and non-alcoholic stea-
tohepatitis (NASH) are the most common causes of liver
cirrhosis [1]. Diagnosis of liver cirrhosis is usually based
on physical examination, blood tests and sonography
and liver biopsy is in general not necessary [1]. Liver
dysfunction and portal hypertension in liver cirrhosis
can lead to serious complications, and the most com-
mon are varices, ascites and hepatic encephalopathy [2].
The Child-Pugh score is used to assess the severity of
liver dysfunction in the clinic. This score includes asci-
tes, hepatic encephalopathy, total bilirubin, albumin,
prothrombin time or international normalized ratio
(INR) [3]. Model for end-stage liver disease (MELD)
score was first approved for the prediction of the sur-
vival of patients undergoing transjugular intrahepatic
portosystemic shunts (TIPS) [3]. The MELD score in-
cludes INR, total bilirubin and creatinine and nowadays
is used for the prioritization of liver transplantation can-
didates [3].
The liver is the central organ in lipid metabolism, and
abnormalities of lipoproteins are common in patients
with liver cirrhosis. Low density (LDL) and high density
lipoprotein (HDL) were reduced in patients with liver
cirrhosis in comparison to liver-healthy controls and
were lowest in patients with decompensated disease [4–
6]. Lipoprotein particles contain cholesterol [7] and
serum cholesterol was accordingly low in liver cirrhosis
[8]. Cholesterol concentration of LDL is about 4-fold
higher than levels in HDL particles [7] and both lipopro-
teins declined in liver cirrhosis patients [9].
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
plays a key role in cholesterol metabolism. PCSK9 pro-
motes the lysosomal degradation of the LDL-receptor
and increases plasma LDL cholesterol [10, 11]. Targeting
PCSK9 is a promising, but costly approach, to treat
hypercholesterolemia [10, 11].
Lipid metabolism is disturbed in patients with NASH
suggesting a role of PCSK9 herein. In morbidly obese
patients hepatic PCSK9 protein was reduced in the pa-
tients with fatty liver whereas associations with hepatic
inflammation and hepatocyte ballooning did not exist
[12]. Although positive correlations of circulating PCSK9
with hepatic steatosis and markers of liver injury existed
in some cohorts [12, 13] such associations could not be
identified in other studies [14].
The function of PCSK9 beyond its role in cholesterol
metabolism is not well understood [10]. PCSK9 posi-
tively correlated with C-reactive protein (CRP) and white
blood cell number indicating a role in the immune re-
sponse [15]. In fact, PCSK9 production was induced by
inflammatory stimuli and by itself was a proinflamma-
tory factor [10, 16, 17]. PCSK9 inhibition thus sup-
pressed nuclear factor kappa B activation and attenuated
inflammation in experimental colitis [18]. PCSK9 defi-
cient mice challenged with lipopolysaccharide (LPS) had
reduced circulating levels of proinflammatory cytokines
[19]. The effects of PCSK9 blockage were abrogated in
LDL-receptor deficient mice. This suggests that bacterial
lipids such as LPS were cleared via the LDL-receptor.
Interestingly, LPS response was also attenuated in
humans with PCSK9 loss-of-function mutations [19].
Dysregulation of the immune response in patients with
liver cirrhosis contributes to fibrosis [20]. Inflammatory
biomarkers were related to patients’ survival and the
prognostic value of IL-6 for mortality was comparable
with the MELD score [21]. Blockage of PCSK9 enhanced
LPS clearance and ameliorated systemic and hepatic in-
flammation in a rat model of liver cirrhosis [22]. PCSK9
inhibition moreover was effective in a rodent model of
alcoholic liver disease, and improved hepatic inflamma-
tion [23]. Even though these experimental data suggest
PCSK9 inhibitors as valuable options in patients with
liver cirrhosis, low serum PCSK9 was associated with
a higher mortality in patients with end-stage liver dis-
ease [24]. In this cohort, serum PCSK9 was negatively
correlated with the MELD score, bilirubin and INR
[24]. A separate study reported on increased serum
PCSK9 values in patients with liver cirrhosis com-
pared to non-cirrhotic patients with chronic liver dis-
ease. This was in line with higher levels of PCSK9
protein in the cirrhotic liver [25]. In patients with
liver cirrhosis, serum cholesterol and PCSK9 concen-
trations were not correlated [24].
In human carriers of a PCSK9 loss-of-function variant
(R46L), distinct cholesteryl ester and sphingolipid spe-
cies were reduced as compared to carriers of the major
allele [26]. LDL-cholesterol did not significantly differ
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between these two groups and variations in serum
sphingolipid composition could be a more sensitive
markers of PCSK9 activity [26]. Lipoproteins contain
sphingolipids and about 60% of serum ceramide and 30
to 50% of serum sphingomyelin are part of LDL parti-
cles. HDL carries about 25% of serum ceramide and
about 40% of serum sphingomyelin [7, 27]. Enhancing
the hepatic uptake of LDL most likely lowers serum
cholesterol and other lipids including ceramide and
sphingomyelin. A general decrease of lipids was indeed
detected in LDL particles of patients with coronary heart
disease who were treated with a PCSK9 inhibiting anti-
body [28].
In this study we hypothesized that systemic PCSK9
levels correlate with cholesterol and / or sphingolipid
species and possibly parameters of inflammation in pa-
tients with liver cirrhosis. Regarding that PCSK9 is
highly expressed in the liver [29], we postulated a nega-




Thirty eight patients with liver cirrhosis were included
in the study. Cirrhosis was diagnosed by physical
examination, sonography and laboratory values. Details
of the cohort are listed in Table 1. The causes for liver
cirrhosis were alcohol abuse in 31 patients, chronic
hepatitis C (HCV) infection in 3 patients and of different
etiologies in 4 patients. Transjugular intrahepatic porto-
systemic shunt (TIPS) (Viatorr-Stent, Putzbrunn,
Germany) implantation was done in the morning in the
fasted patient [30]. TIPS was inserted in 12 patients with
variceal bleeding, in 1 patient with hepatorenal
syndrome, in 24 patients with refractory ascites and in 1
patient where the reason for stent insertion was not doc-
umented. Ascites volume was defined as: little = ascites
only detected by ultrasound; massive = extensive and
bulging ascites; modest = in between little and massive.
Small varices disappeared in endoscopy during air insuf-
flation and large varices did not.
During TIPS, EDTA plasma was obtained from the
hepatic vein (HVP), the portal vein (PVP) and from a
peripheral vein (SVP). These blood samples were used in
former studies [31–35] and there was enough material
left from HVP and PVP of 38 patients and of SVP of 31
patients. Plasma was also collected shortly after TIPS,
and HVP of 37 patients, PVP of 38 patients and SVP of
38 patients were available. Serum of 26 of these patients
was accessible. Laboratory parameters were provided by
Table 1 Patient demographics and laboratory parameters (C-reactive protein, CRP; alanine aminotransferase, ALT; aspartate
aminotransferase, AST). Median values and range of the values are shown. Superscript digits were added when the respective
information was not available for the whole study group and correspond to the number of patients where these data were








Number 38 26 55
Sex (female/male) 9/29 5/21 23/32
Age (years) 53 (26–81) 49 (40–81) 58 (21–80)
Child-Pugh score A/B/C/nd 10/13/15/0 8/7/7/4 na
MELD score 9 (6–21) 8 (6–21) 22 na
Ascites: no / little / modest / massive /nd 4/11/4/19/0 6/9/2/8/1 na
Variceal size: no / small / large / nd 6/7/25/0 5/4/16/1 na
C-reactive protein (mg/L) 14.4 (1.0–53.5) 35 13.9 (2.0–46.7) 20 nd
Fibrinogen (mg/dL) 263 (114–520) 37 349 (151–515) 22 nd
Antithrombin 3 (%) 63.7 (23.6–100.0) 34 65 (23.6–92.8) 21 nd
Factor V (%) 59 (17–137) 25 61 (17–127) 20 nd
ALT (U/l) 38 (4–108) 38 (7–108) 32 (16–288) 54
AST (U/l) 30.0 (2–84) 29 (2–73) 24 (12–256) 54
Albumin (g/L) 31.2 (1.6–47.0) 31.5 (1.6–4.1) 46.8 (31.6–55.6) ***
Bilirubin (mg/dL) 1.2 (0.3–8.2) 1.1 (0.4–3.7) 0.5 (0.2–2.8) 53 ***
Quick prothrombin time (%) 72 (28–100) 76 (44–100) 22 nd
Creatinine (mg/dL) 1.1 (0.5–4.5) 1.0 (0.6–4.5) 22 nd
LDL (mg/dL) 60 (6-128) 35 (17–81) 112 (44–340)52 ***
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the local Institute of Clinical Chemistry and Laboratory
Medicine. Analysis of cholesteryl ester and sphingolipid
species in our patients with liver cirrhosis has been done
before and data were published [36]. This study revealed
a negative association of circulating cholesterol with the
MELD score [36].
The control cohort included patients referred to ultra-
sound imaging (Table 1). Patients with cancers, severe
liver diseases or liver cirrhosis were excluded. Serum but
not plasma was collected from these patients (Table 1).
Tumor-adjacent liver tissues of patients undergoing
surgery because of hepatocellular carcinoma were used
for immunoblot analysis. These patients were described
in detail in a previous work, which was published in an
open access journal and data are therefore freely
accessible [37].
Measurement of lipids
Analysis of lipids was recently described in detail [36].
Quantification used direct flow injection electrospray
ionization tandem mass spectrometry [38, 39]. Not nat-
urally occurring lipid species served as internal stan-
dards. Dissolved samples (10 mM ammonium acetate in
methanol/chloroform (v/v)) were injected with a HTS
PAL autosampler (Zwingen, Switzerland). A flow gradi-
ent (55 μl/min for 0.1 min, 30 μl/min for 1.0 min and an
increase to 250 μl/min (0.2 min)) was used. The triple
quadrupole mass spectrometer has an electrospray ion
source which operates in positive mode (Quattro Ultima,
Micromass, Manchester, UK).
A fragment ion of m/z 184 was used for sphingomye-
lin (SM), and of m/z 264 for ceramides [40]. Cholesteryl
ester (CE) species were quantified by using a fragment of
m/z 369, and CE 17:0/ 22:0 and deuterated D (7)-free
cholesterol were used as internal standards [38].
PCSK9 ELISA
The human PCSK9 DuoSet ELISA was used (R&D Sys-
tems; Wiesbaden, Nordenstadt, Germany) as specified by
the provider (dilution 1:100). Resistin, galectin-3, IL-6,
adiponectin, leptin, chemerin and pentraxin 3 were
measured in serum / plasma before [31–35].
SDS-polyacrylamide gel electrophoresis and
immunoblotting
These techniques were described [37]. For quantification
of signals ImageJ software was used [41]. C-reactive pro-
tein (CRP) and LDL-receptor antibodies were from R&D
Systems. PCSK9 antibody and alpha-smooth muscle
actin antibodies (alpha-SMA) were from Cell Signalling
Technology (Danvers, MA, USA).
Fig. 1 PCSK9 and LDL in serum of patients with and without liver cirrhosis. a LDL in serum of patients with and without liver cirrhosis (Controls).
b PCSK9 in serum of patients with and without liver cirrhosis (Controls). c Correlation of PCSK9 and LDL in the control cohort. d Correlation of
PCSK9 and LDL in the cirrhosis cohort. * P < 0.05
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Statistics
Data are visualized as box blot charts. The circles in the
figures represent outliers greater than 1.5 times, and the
asterisks outliers greater than 3.0 times the interquartile
range. Statistical tests used were Mann-Whitney U Test,
one-way ANOVA and Spearman correlations (IBM SPSS
Statistics 25.0). The chi square test was used for categor-
ical variables. A P value < 0.05 was considered
significant.
Results
PCSK9 in serum of patients with and without liver
cirrhosis
LDL is low in patients with liver cirrhosis [8] and was
also reduced in the serum of the 26 patients with liver
cirrhosis participating in the current study in compari-
son to the 55 non-cirrhotic patients (Fig. 1a). PCSK9
was also low in serum of liver cirrhosis patients (Fig. 1b).
Positive correlations of PCSK9 and LDL existed in the
non-cirrhotic patient group but not the cirrhotic patients
(Fig. 1c, d).
PCSK9 is highly expressed in the liver [29], and im-
paired liver function may contribute to lower PCSK9
levels in the hepatic vein of these patients. Serum of suf-
ficient patients was not available to clarify whether
hepatic PCSK9 release is indeed associated with residual
liver function. Therefore, plasma was used for this
analysis.
PCSK9 in peripheral, hepatic and portal venous plasma of
patients with liver cirrhosis
Plasma of 38 patients with clinically diagnosed liver cirrho-
sis was available. PCSK9 was measured by ELISA in sys-
temic vein plasma (SVP), hepatic vein plasma (HVP) and
portal vein plasma (PVP). PCSK9 plasma concentrations
did not differ by gender (Fig. 2a) and were not related to
age (data not shown). Correlations existed for SVP and
PVP PCSK9 (r = 0.769, p < 0.001), SVP and HVP PCSK9
(HVP, r= 0.779, p < 0.001) and PVP and HVP PCSK9 (r =
0.809, p < 0.001) (Fig. 2b, c and data not shown).
PCSK9 levels were comparable in SVP, HVP and PVP
(Fig. 2d). The three patients with viral disease etiology
had higher PCSK9 plasma levels in SVP (P = 0.015),
HVP (Fig. 2e; P = 0.016) and PVP (P = 0.014) than pa-
tients with alcoholic liver cirrhosis. Ascites and variceal
bleeding were the main complications of liver cirrhosis
in the patients, but PCSK9 in HVP (Fig. 2f), SVP and
PVP (data not shown) did not differ between the two
cohorts.
Fig. 2 PCSK9 in plasma of patients with liver cirrhosis. a PCSK9 levels in females (F) and males (M). b Correlation of hepatic vein plasma (HVP) and
portal vein plasma (PVP) PCSK9. c Correlation of systemic vein plasma (SVP) and PVP PCSK9. d PCSK9 in SVP, HVP and PVP. e HVP PCSK9 in 31
patients with alcoholic and 3 patients with viral disease etiology. f HVP PCSK9 in 12 patients and 24 patients, respectively, where variceal bleeding
or ascites were the major complication. *** p < 0.001
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Association of PCSK9 with the severity and complications
of liver cirrhosis
The Child-Pugh and the MELD scores are used to as-
sess the prognosis of liver cirrhosis [42]. No differ-
ences were observed in plasma PCSK9 levels between
patients with Child-Pugh scores A, B and C (Fig. 3a
and data not shown). PCSK9 levels in SVP, HVP and
PVP were not correlated with the MELD score in the
whole cohort and when patients with non-alcoholic
disease etiology were excluded (Fig. 3b and Table 2).
PCSK9 plasma concentrations did not change with as-
cites volume or variceal size (Fig. 3c, d). Ascites and
varices are serious complications and are related to
the hepatic venous pressure gradient (HVPG) [43].
HVPG of 36 patients was documented but was not
correlated with PCSK9 in any blood compartment
(data not shown). Transjugular intrahepatic portosys-
temic shunting reduced HVPG (p < 0.001, HVPG of
29 patients was documented) whereas PCSK9 was not
changed (Fig. 3e). This finding further excluded an
association of HVPG and PCSK9 levels.
Hepatic PCSK9 and LDL-receptor protein in liver cirrhosis
PCSK9 is expressed in the liver and murine data showed
that the liver predominately contributed to serum
PCSK9 levels [29]. Having shown that plasma PCSK9
did not decline with measures of liver disease severity it
was suggested that hepatic PCSK9 expression may also
be unaffected. PCSK9 protein was analysed by immuno-
blot in the liver of patients with chronic liver diseases.
Liver cirrhosis was defined by histology, and 3 of the 10
patients with hepatitis B had cirrhosis. In patients with
chronic HCV infection 8 of the 11 patients had liver cir-
rhosis and in patients with non-viral liver disease 1 of
the 11 patients had liver cirrhosis. Alpha-smooth muscle
actin (alpha-SMA) is induced in liver cirrhosis and, as
expected, was positively correlated with fibrosis stage
(Fig. 4a - c; r = 0.392, P = 0.026). PCSK9 (r = 0.316, P =
0.083) and the LDL-receptor protein (r = 0.174, P =
0.340) did not correlate with fibrosis stage and were not
reduced in the patients with liver cirrhosis when com-
pared to patients with fibrosis stage 0 to 3 (Fig. 4a - e
and data not shown). Of note, hepatic PCSK9 protein
positively correlated with hepatic LDL-receptor protein
(Fig. 4f).
HCV infected patients had higher plasma PCSK9 (Fig.
2e) and comparison of PCSK9 protein in the liver of five
patients infected with HCV and five patients with non-
viral liver disease revealed that PCSK9 was induced in
HCV (Fig. 4g, h). LDL-receptor protein was also higher
in the liver of HCV patients (Fig. 4i). C-reactive protein
(CRP) was not changed in the liver of the HCV patients,
excluding that protein levels were generally higher in
HCV liver (Fig. 4g).
Fig. 3 Associations of PCSK9 with Child-Pugh and MELD score and complications of liver cirrhosis. a PCSK9 in hepatic vein plasma (HVP) of patients
stratified for Child-Pugh scores. b Correlation of HVP PCSK9 with the MELD score. c HVP PCSK9 in patients without (No), little, modest and massive
ascites. d HVP PCSK9 in patients without, with small and large varices. e PCSK9 in the three compartments before and shortly after TIPS
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Correlation of plasma PCSK9 with laboratory parameters
of hepatic and kidney function
PCSK9 levels did not correlate with bilirubin, Quick pro-
thrombin time, aspartate aminotransferase, alanine ami-
notransferase, fibrinogen, antithrombin 3, factor V or
creatinine in any blood compartment (Table 2). Albumin
negatively correlated with SVP PCSK9 whereas HVP and
PVP PCSK9 levels were not related to albumin (Table
2). These associations persisted when the patients with
non-alcoholic disease etiology were excluded from the
calculation (Table 2).
Associations with circulating inflammatory markers and
adipokines
PCSK9 is upregulated by inflammatory mediators [10].
PCSK9 in any of the three blood compartments did,
however, not correlate with CRP (Table 3). Moreover,
there were no associations of PCSK9 with the immune-
regulatory proteins galectin-3 and resistin [20, 44, 45]
(Table 3). Pentraxin 3 is an adequate indicator of
inflammation in patients with liver cirrhosis [46] but was
not related to PCSK9 levels in any of the blood compart-
ments (Table 3). Moreover, PCSK9 did not correlate
with interleukin-6 (IL-6) in SVP, HVP or PVP (Table 3).
Chemerin is highly expressed in hepatocytes and
correlates with circulating markers of inflammation in
distinct patient cohorts [47–49]. HVP chemerin was in-
deed positively associated with hepatic vein PCSK9
(Table 3). Adiponectin and leptin are adipokines with a
function in liver fibrosis [20]. In HVP there was a mod-
est, inverse correlation of PCSK9 and adiponectin (Table
3). Associations of PCSK9 with adiponectin and che-
merin were still significant in the subgroup of patients
with alcoholic disease etiology (Table 3). Leptin was not
related to PCSK9 concentrations in any of the blood
compartments (Table 3).
Associations of plasma PCSK9 with cholesterol and
sphingolipids
Previous studies identified correlations between PCSK9,
total and LDL cholesterol [10, 11, 28, 50]. Levels of free
cholesterol, cholesteryl ester and sphingolipid species
were determined in the serum of our patient cohort and
these data were already published. This cohort initially
included 45 patients (plasma of 7 patients was used up),
and a negative correlation of cholesterol with the MELD
score existed [36]. PCSK9 did not correlate with total
cholesterol (which is the sum of all cholesteryl esters
and free cholesterol) (r = − 0.282, p = 0.13), the sum of
the cholesteryl ester levels (r = − 0.28, p = 0.13) or free
cholesterol (r = − 0.279, p = 0.14) (Fig. 5a and data not
shown). Moreover, PCSK9 did not correlate with total
ceramide or sphingomyelin levels (Fig. 5b, c). Associa-
tions with individual ceramide or sphingolipid species
could not be identified (data not shown). Referring to in-
dividual cholesteryl ester species there was a negative
correlation of PCSK9 with CE 20:5 (Fig. 5d).
Serum cholesterol and sphingolipids in patients with high
and low PCSK9
High PCSK9 is usually associated with high cholesterol
and the negative association with CE 20:5 was not
expected. To investigate this in more detail the patient
cohort was classified into two study groups according to
the median SVP PCSK9 concentration (148.4 ng/mL),
i.e. 16 patients with PCSK9 below the median and 15 pa-
tients with levels higher than the median (Fig. 6a and
Table 4). These two groups had comparable age, MELD
score, ALT, AST, bilirubin, CRP, resistin, galectin-3, IL-
6, pentraxin 3, adiponectin and chemerin levels (data
not shown). Albumin (p = 0.001) was lower in the group
with high PCSK9. Total cholesteryl ester levels tended to
be lower (p = 0.05, Fig. 6b). CE 16:0, 20:5, 20:4, 22:6 and
22:4 were indeed significantly diminished in the patients
Table 2 Correlation coefficients of PCSK9 in the different blood
compartments of all patients with MELD score, bilirubin,
aspartate aminotransferase (AST), alanine aminotransferase (ALT),
Quick prothrombin time, antithrombin 3, fibrinogen, factor V
and creatinine, which were measured in peripheral blood.
Highlighted in yellow are the correlation coefficients in the
subgroup of patients with alcoholic disease etiology. Superscript
digits indicate number of patients where these data were
available. * P < 0.05, ** P < 0.01
PCSK9 HVP PVP SVP
MELD 0.070 37 0.079 38 0.084 31
−0.126 31 0.008 31 0.094 26
Bilirubin −0.096 38 −0.055 38 − 0.018 31
−0.234 31 − 0.246 31 −0.119 26
AST −0.015 38 0.140 38 0.276 31
−0.165 31 −0.043 31 0.123 26
ALT −0.251 38 −0.094 38 − 0.029 31
−0.342 31 − 0.232 31 −0.086 26
Albumin −0.115 38 −0.030 38 − 0.476 31 **
−0.085 31 0.027 31 −.471 26 *
Quick Prothrombin Time 0.223 38 0.181 38 0.277 31
0.179 31 0.167 31 0.317 26
Antithrombin 3 0.277 34 0.312 34 0.308 27
0.303 29 0.367 29 0.350 24
Fibrinogen 0.134 37 0.127 37 0.224 30
0.215 30 0.215 30 0.336 25
Factor V 0.023 25 0.064 25 0.169 20
−0.087 22 −0.046 22 0.020 18
Creatinine 0.002 38 0.098 38 0.078 31
0.048 31 0.130 31 0.173 26
Feder et al. Lipids in Health and Disease            (2021) 20:6 Page 7 of 14
with higher PCSK9 (Table 4). Total ceramide and
sphingomyelin (SM) levels were essentially the same in
both subgroups (Fig. 6c, d). SM 18:0, 20:1, 24:2 and 24:1
were nevertheless lower in the group with high PCSK9
(Table 5).
Discussion
In patients with liver cirrhosis the present study demon-
strated that plasma PCSK9 was neither associated with
the severity of liver cirrhosis nor its complications.
PCSK9 did not positively correlate with serum choles-
terol and sphingolipids, which are carried in LDL parti-
cles. In fact, in patients with liver cirrhosis, impaired
hepatic function seems to override the effect of PCSK9
on cholesterol metabolism, as demonstrated by the loss
of the correlation between cholesterol and PCSK9. Actu-
ally, distinct cholesteryl ester species even declined in
patients with PCSK9 levels above the median
Fig. 4 PCSK9 and LDL-receptor protein in the liver of patients with chronic liver diseases. PCSK9, LDL-receptor, alpha-SMA and GAPDH protein in
the liver of patients with a chronic HBV infection, b chronic HCV infection and c non-viral liver disease. The respective fibrosis stages are listed
below the figure panels. LC is the loading control and was used for normalization of the different immunoblots. d Correlation of hepatic PCSK9
protein with fibrosis stage. e PCSK9 in the liver of patients with fibrosis stage 0 to 3 (non-cirrhosis) and in patients with liver cirrhosis (fibrosis
stage 4). f Correlation of hepatic PCSK9 and LDL-receptor protein. g PCSK9, LDL-receptor, CRP and GAPDH protein in the liver of patients with
chronic HCV infection (patient number 1, 3, 5, 7, 9) and non-viral disease (patient number 2, 4, 6, 8, 10). The respective fibrosis stages are listed
below the figure. h Quantification of PCSK9 and i LDL-receptor in the liver of patients with chronic HCV infection and non-viral disease.
Coomassie stained membranes are shown to further confirm equal loading of the immunoblots. ** P < 0.01, *** P < 0.001
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concentration in comparison to patients with PCSK9
levels below the median. Though the mechanisms of
these associations have not been finally resolved, this
finding excludes a role of PCSK9 in alcoholic cirrhosis
related hypocholesterolemia. Of note, a positive correl-
ation of PCSK9 and LDL-receptor protein existed in the
liver of patients with chronic liver diseases. Thus, PCSK9
mediated degradation of the LDL-receptor protein is
hindered in the diseased liver by a so far unknown
mechanism.
A lack of correlation between cholesterol and PCSK9
was also reported in a cohort of patients with severe
liver disease where the MELD score ranged from 7 to
40, with a mean score of 21 [24]. This study described a
negative association of PCSK9 and the MELD score and
a higher mortality of patients with low PCSK9 [24]. It
could be suggested that impaired hepatic synthesis of
PCSK9 is a consequence of the severely disturbed liver
function of patients with very high MELD scores [24].
Noteworthy, PCSK9 correlated with parameters of liver
function like albumin supporting this assumption [24].
The MELD score of our patients ranged from 6 to 21
and, in contrast to the study described above, was not
related to PCSK9 levels. In patients with PCSK9 above
the median value albumin was lower in comparison to
patients with PCSK9 levels below the median. Moreover,
analysis of the association between PSCK9 and albumin
Table 3 Correlation coefficients of PCSK9 in the different blood
compartments with CRP measured in serum, and resistin,
galectin-3, pentraxin 3, chemerin, adiponectin, leptin and IL-6
measured in the respective blood compartments. Highlighted in
yellow are the correlation coefficients in the subgroup of
patients with alcoholic disease etiology. Superscript numbers
indicate the number of patients where these data were
available. * P < 0.05, ** P < 0.01
PCSK9 HVP PVP SVP
CRP (peripheral) 0.076 35 0.203 35 0.308 30
−0.047 29 0.081 29 0.225 25
Resistin 0.017 34 0.074 34 −0.008 29
−0.045 28 0.036 28 −0.046 24
Galectin-3 −0.118 34 0.262 34 0.181 29
−0.36328 0.096 28 −0.029 24
Pentraxin 3 −0.080 34 0.008 34 −0.034 26
−0.030 30 0.093 29 0.104 23
Chemerin 0.427 38** 0.327 38 0.300 31
0.365 31* 0.222 31 0.218 26
Adiponectin −0.367 34* −0.204 34 −0.107 29
−0.397 28* −0.215 28 − 0.080 24
Leptin 0.246 34 0.068 34 0.212 29
0.229 28 - 0.073 28 0.187 24
IL-6 −0.107 20 − 0.244 20 0.212 20
−0.232 16 −0.382 16 0.203 13
Fig. 5 Associations of PCSK9 with cholesterol and sphingolipids in patients with liver cirrhosis. a Correlation of systemic vein plasma (SVP) PCSK9
with cholesterol (which is the sum of all cholesteryl esters and free cholesterol). b Correlation of SVP PCSK9 with ceramide. c Correlation of SVP
PCSK9 with sphingomyelin (d) Correlation of SVP PCSK9 with cholesteryl ester (CE) 20:5. ** P < 0.01
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revealed a significant negative correlation. Thus, our find-
ings do not support an association of circulating PCSK9
and residual liver function at least in patients with alco-
holic liver cirrhosis. A separate study observed higher hep-
atic PCSK9 protein in the cirrhotic compared to the non-
cirrhotic liver [25]. Bhat et al. further described a signifi-
cant positive correlation of hepatic PCSK9 protein with
the stages of liver fibrosis [25]. In that study 85% of pa-
tients had liver cirrhosis, and only 6 patients had fibrosis
stage 0, 2 or 3 [25]. In the tissues analysed herein 12 pa-
tients had cirrhosis and 20 patients had fibrosis stage 0, 1,
2 or 3, and therefore, the cohort may be better suited to
identify associations of hepatic PCSK9 protein and stages
of liver fibrosis.
Analysis of hepatic PCSK9 protein in patients with
viral and non-viral disease etiology failed to identify
higher levels in the cirrhotic liver. Similarly, PCSK9 pro-
tein did not change with increasing liver disease severity
in patients with NAFLD [12].
So far it is unclear whether the etiology of liver cirrho-
sis has an effect on circulating PCSK9. Comparison of
hepatic PCSK9 protein in patients with viral and non-
viral related liver diseases showed that PCSK9 protein
was strongly induced in HCV liver. In line with a
previous study, LDL-receptor protein was also high in
the liver of HCV patients [51]. The LDL-receptor is in-
volved in hepatitis C virus (HCV) entry, and PCSK9 was
supposed to protect from HCV infection [52]. The three
patients with HCV cirrhosis had higher plasma PCSK9
than patients with alcoholic etiology. Indeed, increased
and reduced PCSK9 levels were observed in HCV pa-
tients [53] and HCV genotype or comorbidities may be
potential confounding factors.
In the study by Schlegel et al. showing correlations of
PCSK9 with the MELD score the underlying etiologies
varied and 62% of the patients had alcoholic liver dis-
eases. The other patients had non-alcoholic fatty liver
disease, HCV, cryptogenic cirrhosis, Budd-Chiari syn-
drome and autoimmune hepatitis [24]. Separate analysis
of the patients with alcoholic liver disease was not per-
formed [24] adding to the differences between the data
of the present examination and the study by Schlegel
et al. [24].
Median PCSK9 was 148 ng/mL in our patient cohort
and 106 ng/mL in the cohort with very severe liver dis-
eases [24]. PCSK9 concentrations described in the litera-
ture range from about 50 to 600 ng/mL and may vary
according to the underlying disease [10, 24, 25, 54–56].
Fig. 6 PCSK9 and lipids in patients with PCSK9 levels below or above the median plasma value. a PCSK9 in patients with PCSK9 below or above
the median value. b Cholesteryl ester (CE) levels in patients with PCSK9 below or above the median value. c Ceramide in patients with PCSK9
below or above the median value. d Sphingomyelin in patients with PCSK9 below or above the median value. *** P < 0.001
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The high variation of PCSK9 in the different studies fur-
ther suggests that absolute concentrations may vary de-
pending on the type of ELISA assay used. It is not
recommended to compare PCSK9 levels determined by
different assays. Therefore, we measured PCSK9 in
serum of non-cirrhotic controls and patients with liver
cirrhosis. Serum PCSK9 was lower in the patients with
liver cirrhosis. Positive associations of PCSK9 and LDL
existed in the non-cirrhotic patients. This association
was lost in liver cirrhosis patients. In the cohort analysed
by Bhat et al. serum PCSK9 was 92 ng/mL in the 6
healthy controls and 78 ng/mL in the 13 cirrhosis pa-
tients, also suggesting a decline of circulating PCSK9 in
liver cirrhosis [25].
Most ELISAs for PCSK9 measurement can not distin-
guish between intact PCSK9 and its truncated, inactive
form [57]. This latter isoform is produced by furin cleav-
age and represents 3 to 42% of systemic PCSK9 [57]. Cor-
relation coefficients with LDL-cholesterol did not improve
when concentrations of intact PCSK9 instead of total
PCSK9 levels were used for calculation [57]. So far levels
of intact and cleaved PCSK9 were not determined in liver
cirrhosis patients. The missing correlation of circulating
PCSK9 with cholesterol may be also caused by a high level
of inactive PCSK9 in patients with liver cirrhosis, a sugges-
tion which has to be proven in the future.
Discordant findings regarding the association of circu-
lating PCSK9 and liver function [24, 25] suggest that
additional factors affect circulating PCSK9. PCSK9 is
highly expressed in the intestine and small intestinal
bacterial overgrowth is common in patients with liver
cirrhosis [58, 59]. LPS induced hepatic PCSK9 but
whether intestinal PCSK9 production was affected by
LPS or was associated with liver disease severity was not
evaluated in that study [59]. Intestinal PCSK9 did not
regulate plasma lipids and did not contribute to PCSK9
plasma levels [60]. Accordingly, the current analysis
showed that PCSK9 concentrations did not differ be-
tween the portal and the hepatic vein.
Systemic inflammation contributes to the progression
of liver cirrhosis [61] and LPS increased hepatic PCSK9
expression in mice [62]. Therefore, associations of
PCSK9 with circulating inflammatory proteins were ana-
lysed in our cohort. CRP is an acute phase protein and is
produced in the liver in response to IL-6 [20]. Pentraxin
3 is expressed by vascular smooth muscle cells and
endothelial cells at the site of inflammation and is an in-
dependent inflammatory biomarker [46]. Analysis of the
association between PCSK9, IL-6 and CRP or pentraxin
3 revealed no significant correlations. This also applied
for resistin and galectin-3, which are both induced in
activated immune cells [20].
Table 4 Median, minimum and maximum values of cholesteryl ester (CE) species in patients with PCSK9 levels below and above
the median level. *P < 0.05, ** P < 0.01
PCSK9 (ng/mL) and CE
species (μmol/L)
SVP PCSK9 below the median level
(16 patients)
SVP PCSK9 above the median level
(15 patients)
P-value
Median Min Max Median Min Max
PCSK9 101.7 9.4 148.2 211.1 156.8 1362.3 **
CE 14:0 15.3 7.0 28.6 15.3 5.2 25.0
CE 15:0 5.1 2.3 11.8 4.4 1.6 7.6
CE 16:1 110.3 43.8 213.5 94.5 37.3 200.5
CE16:0 256.4 100.4 418.9 177.7 71.4 285.5 *
CE18:3 21.5 12.2 61.6 21.4 6.5 40.5
CE 18:2 839.7 385.5 1817.4 611.3 248.6 1200.1
CE 18:1 381.2 168.1 672.9 307.3 105.2 452.8
CE 18:0 5.6 3.1 21.7 6.1 2.3 13.8
CE 20:5 8.9 3.4 18.9 4.7 2.3 8.8 **
CE 20:4 123.3 34.9 214.4 54.9 23.1 102.9 **
CE 20:3 12.1 3.5 35.5 8.8 3.5 15.6
CE 20:2 0.9 0.4 2.9 0.7 0.0 1.6
CE 20:1 0.6 0.3 2.8 0.5 0.2 1.9
CE 20:0 0.8 0.5 1.5 0.7 0.6 1.1
CE 22:6 6.4 2.1 14.8 3.9 1.9 8.9 **
CE 22:5 1.3 0.3 2.9 0.9 0.5 2.6
CE 22:4 0.5 0.2 1.6 0.4 0.0 1.3 *
CE 22:1 0.4 0.2 1.4 0.3 0.0 0.7
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In the cohort studied in the current work, PCSK9 was
negatively correlated with adiponectin and positively with
chemerin in the hepatic vein. Adiponectin is regarded as
an anti-inflammatory and antifibrotic adipokine [63]. The
role of chemerin in the liver was less well analysed but
several studies identified positive correlations of systemic
chemerin and inflammatory cytokines [47, 49]. Recombin-
ant chemerin added to culture media did not regulate
PCSK9 in hepatocellular carcinoma cell lines [64] and
there is no evidence that PCSK9 affects hepatocyte che-
merin expression. Serum chemerin is positively and adipo-
nectin is negatively associated with an unfavourable
metabolic phenotype in a population-based cohort study
[65]. Such associations may change in severely ill patients
including patients with liver cirrhosis [20]. Serum adipo-
nectin was induced in liver cirrhosis patients and this may
be a consequence of impaired hepatic excretion [20]. On
the other hand, chemerin declined in parallel with the se-
verity of liver disease [66]. This suggests that associations
of PCSK9 and the adipokines chemerin and adiponectin
in the hepatic vein possibly reflect the activity of certain
pathways which are impaired in liver cirrhosis.
The liver is the major source of plasma PCSK9 at least
in mice [29] and hepatic LDL-receptors are major
regulators of PCSK9 clearance [67]. Similar PCSK9 con-
centrations in the hepatic and the portal vein suggest
that hepatic synthesis and clearance of PCSK9 must be
equal. The half-life of PCSK9 in blood is about 5 min
[67] and hepatic synthesis seems to compensate for loss
of blood PCSK9.
Study strengths and limitations
The strength of this study is that plasma collected from
the portal and the hepatic vein of patients with liver cir-
rhosis was available. Moreover, individual cholesteryl
ester and sphingolipid species rather than total levels
were measured. Limitations of the present analysis were
that the number of patients enrolled was rather small
and that the exact time points of blood sampling were
not documented. Moreover, possible confounding fac-
tors like medications and nutritional status were not
considered. Liver tissues analysed were from patients
with viral and non-viral disease etiologies but not from
patients with alcoholic liver cirrhosis, and findings may
not be valid for these patients. Future studies should also
discriminate between lipids carried in LDL, HDL and
VLDL particles.
Table 5 Median, minimum (Min) and maximum (Max) values of serum sphingomyelin (SM) species in patients with PCSK9 levels
below and above the median level. * P < 0.05
SM species (μmol/L) SVP PCSK9 below the median level
(16 patients)
SVP PCSK9 above the median level
(15 patients)
P-value
Median Min Max Median Min Max
SM 14:0 4.9 2.7 9.0 4.4 2.0 5.8
SM 15:0 2.9 1.5 4.7 2.3 0.9 3.9
SM16:1 11.2 5.7 22.3 8.0 4.7 16.6
SM16:0 69.2 40.3 126.6 58.6 26.3 86.3
SM 18:2 0.2 0.0 0.9 0.3 0.0 0.6
SM 18:1 5.8 2.4 12.2 3.6 1.8 9.2
SM 18:0 9.8 3.8 18.7 6.2 0.0 12.4 *
SM 20:1 3.0 1.4 5.3 2.3 1.4 3.6 *
SM 20:0 6.1 2.2 9.8 6.9 2.6 11.3
SM 22:2 2.1 0.0 3.9 2.1 0.0 4.5
SM 22:1 12.8 6.8 21.4 10.3 0.0 18.6
SM 22:0 11.2 5.2 20.3 9.2 4.9 16.1
SM 23:1 5.9 2.5 12.3 4.5 2.8 9.0
SM 23:0 3.7 1.1 8.8 2.9 1.7 6.2
SM 24:3 1.6 0.0 3.6 1.5 0.3 4.3
SM 24:2 20.9 10.8 36.6 15.9 10.7 24.2 *
SM 24:1 50.1 36.1 95.0 41.8 18.4 71.2 *
SM 24:0 7.1 4.7 13.6 6.6 3.3 10.9
SM 26:2 0.5 0.0 1.0 0.3 0.0 1.1
SM 26:1 0.5 0.0 1.1 0.3 0.0 0.8
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Conclusions
The present examinations indicate that the negative as-
sociation between the hepatic LDL-receptor protein
levels and PCSK9 was lost in patients with severe liver
diseases. Indeed, levels of these proteins were positively
correlated in the liver. Accordingly, distinct cholesteryl
ester species were even increased in patients with low
plasma PCSK9. Identification of the underlying mecha-
nisms is essential to clarify whether blockage of PCSK9
may be a suitable approach to reduce LDL levels in pa-
tients with severe liver fibrosis.
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